CN-120624444-B - SiRNA-B for inhibiting Zika virus and application thereof

Abstract

The invention discloses siRNA-B for inhibiting Zika virus and application thereof, belonging to the technical field of biology. The sequence of siRNA-B is shown as follows, positive strand 5'-UGUGGUGAAAUCCAUGGUUUC-3' and negative strand 5'-GAAACCAUGGAUUUCACCACA-3'. Compared with vsiRNA-1 sequences known in the prior art, the vsiRNA-B provided by the invention has better effect of inhibiting the Zika virus, and provides a medicament with better curative effect for treating diseases related to the Zika virus.

Inventors

• LEI ZHIWEI
• YUAN HAIYING
• LI GUANGQIANG
• LIN PEIBIN
• ZHANG XIANYING
• LIN SHIYUN
• LIU XIAOFEI

Assignees

• 广州医科大学附属清远医院(清远市人民医院)

Dates

Publication Date

20260505

Application Date

20250611

Claims (10)

1. 1. An siRNA for inhibiting a zika virus, wherein the siRNA has the sequence: Forward chain 5'-UGUGGUGAAAUCCAUGGUUUC-3'; Negative strand 5'-GAAACCAUGGAUUUCACCACA-3'.
2. 2. A vector comprising the siRNA of claim 1.
3. 3. The vector of claim 2, wherein the vector is a viral vector or a liposome vector.
4. 4. A vector according to claim 3, wherein the viral vector is an adenovirus vector.
5. 5. Use of the siRNA of claim 1 or the vector of any one of claims 2-4 in the preparation of a product for inhibiting zika virus.
6. 6. The use according to claim 5, wherein the product is a reagent or a kit.
7. 7. The use according to claim 5, wherein the product is a medicament.
8. 8. Use of the siRNA of claim 1 or the vector of any one of claims 2-4 in the preparation of a product for inhibiting expression of the zhai card virus E protein and/or the NS5 protein.
9. 9. The use according to claim 8, wherein the product is an agent.
10. 10. The use according to claim 8, wherein the product is a kit.

Description

SiRNA-B for inhibiting Zika virus and application thereof Technical Field The invention belongs to the technical field of biology, and particularly relates to siRNA-B for inhibiting Zika virus and application thereof. Background In recent years, ZIKV epidemic situation has a tendency of rapid spread, more than 70 countries and regions have been affected, and global broad-spectrum attention is brought about. Zika virus can cross the blood-fetus barrier to enter the fetus body, which causes abnormal proliferation and differentiation of neural stem cells in the embryo brain, causes massive death of neurons, and causes serious complications, namely neonatal small head deformity. Zika virus (ZIKV) is a single-stranded positive strand RNA virus of the genus Flaviviridae, first found in rhesus monkeys in Uganda Zika forest in 1947 and named therefore. ZIKV viruses are encapsulate icosahedrons with diameters of about 40-60 nm. Mature ZIKV contains a nucleocapsid consisting of linear plus-strand genomic RNA and multiple copies of Viral capsid protein C, and an outer Envelope consisting of 2 Viral: M protein (Viral Membrane), E protein (Viral Envelope) and a lipid bilayer of cell Membrane origin. The M protein is formed by cleavage of the prM protein precursor of the virus by proteases, during assembly of the virion, the prM and E proteins of ZIKV interact and form dimers in the endoplasmic reticulum of the host, at which time the RNA genome of the virus is recognized and encapsulated by the capsid protein C of the virus, which is then recognized and further encapsulated by the dimers formed by the prM and E proteins and the membrane lipid bilayer to form the immature ZIKV virus. Subsequently, prM protein is recognized by the folin protease on the golgi and cleaved into mature M protein, triggering the release of ZIKV virions, which are released extracellularly. The genome of ZIKV virus is a single-stranded positive strand RNA containing a single open reading frame, has a length of about 11000bp, consists of a coding region and two non-coding regions (UTRs) at the 5 'end and the 3' end, and codes 3500 amino acids. The RNA genome of ZIKV virus encodes 3 structural proteins of ZIKV, namely capsid protein C, envelope protein E, membrane precursor protein prM and 7 non-structural proteins of NS1, NS2A, NS2B, NS3, NS4A, NS B and NS5 from N-terminal to C-terminal respectively. The Zika virus can replicate in the epithelial cells of Aedes aegypti and Aedes albopictus and circulate in the blood and saliva of the Aedes aegypti and Aedes albopictus, can be widely spread mainly through biting, can be spread to infect adults and newborns through mosquito vectors and sexual contacts, and can cause various nervous system diseases, such as encephalopathy (Encephalopathy), meningoepitis (Meningoencephalitis), myelitis (Myelitis), guillain-Barre syndrome and the like. More seriously, the Zika virus has extremely strong tropism to human neural stem cells, can penetrate through the blood brain barrier to cause abnormal proliferation and differentiation of the neural stem cells in embryo brain, cause massive death of neurons, cause serious complications, namely neonatal small head malformation and even cause abortion death of fetus. In recent years, the Zika epidemic situation has multiple outbreaks and is in a rapid spreading trend, so that 70 countries and regions are affected to the moment, global wide attention is brought to the Zika virus, the Zika virus becomes a potential factor for threatening global human health, the World Health Organization (WHO) recognizes the Zika virus as an international attention sudden public health event, and Zika virus infection is still a current significant and durable health challenge. However, the current research on replication and pathogenesis of Zika virus is insufficient, and there is still no approved vaccine or specific treatment method for preventing or treating Zika virus infection, so how to cope with the serious challenges of Zika virus infection to human society, and developing specific ZIKV-resistant medicaments for treating related diseases caused by ZIKV infection is the most effective strategy. Disclosure of Invention The invention provides an siRNA for inhibiting Zika virus, which has the following sequence: Forward chain 5'-UGUGGUGAAAUCCAUGGUUUC-3'; Negative strand 5'-GAAACCAUGGAUUUCACCACA-3'. The invention also provides a vector containing the siRNA. Preferably, the vector is a viral vector or a liposome vector. More preferably, the viral vector is an adenovirus vector. The invention also provides application of the siRNA or the vector in preparation of a product for inhibiting the Zika virus. Preferably, the product is a reagent or a kit. Preferably, the product is a medicament. The invention also provides application of the siRNA or the vector in preparation of products for inhibiting expression of the Zika virus E protein and/or the NS5 protein. Preferably, the product is an a